RetinalGenix Technologies (RTGN) Net Cash Flow Growth (1y) (2021 - 2026)
RetinalGenix Technologies (RTGN) Net Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.28 Bn | 193.68 Bn | 7.27 Bn | -562.77% |
| 2 | Stryker | 129.49 Bn | 126.02 Bn | 4.50 Bn | 2,827.78% |
| 3 | Medtronic | 119.55 Bn | 110.33 Bn | 6.41 Bn | 10.50% |
| 4 | Boston Scientific | 73.67 Bn | 73.13 Bn | 3.85 Bn | -395.56% |
| 5 | Edwards Lifesciences | 52.28 Bn | 48.03 Bn | 1.35 Bn | 168.38% |
| 6 | Dexcom | 34.62 Bn | 32.67 Bn | 830.00 Mn | -103.49% |
| 7 | GE HealthCare Technologies | 34.13 Bn | 32.02 Bn | 2.18 Bn | -114.85% |
| 8 | Koninklijke Philips | 26.42 Bn | 23.10 Bn | 4.55 Bn | -215.59% |
| 9 | Steris | 23.17 Bn | 22.69 Bn | 684.20 Mn | -54.17% |
| 10 | RetinalGenix Technologies | 75.02 Mn | 75.02 Mn | - | -521.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -521.29% |
| Dec 31, 2025 | 120.10% |
| Sep 30, 2025 | 90.45% |
| Jun 30, 2025 | -107.86% |
| Mar 31, 2025 | -104.66% |
| Dec 31, 2024 | -165,875.00% |
| Sep 30, 2024 | -318.62% |
| Jun 30, 2024 | 757.32% |
| Mar 31, 2024 | 577.96% |
| Dec 31, 2023 | 98.77% |
| Sep 30, 2023 | -148.02% |
| Jun 30, 2023 | -119.82% |
| Mar 31, 2023 | 410.70% |
| Dec 31, 2022 | 88.70% |
| Sep 30, 2022 | -88.98% |
| Jun 30, 2022 | -1,561.27% |
| Mar 31, 2022 | -110.93% |
| Dec 31, 2021 | -13.49% |